AWM Investment Company Inc. Makes New $9.81 Million Investment in SOPHiA GENETICS SA $SOPH

AWM Investment Company Inc. bought a new position in SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,700,000 shares of the company's stock, valued at approximately $9,809,000. AWM Investment Company Inc. owned about 2.03% of SOPHiA GENETICS as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the fourth quarter valued at $49,000. Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS in the third quarter worth $49,000. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS during the 1st quarter worth about $50,000. Quadrature Capital Ltd bought a new position in SOPHiA GENETICS during the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $55,000. Institutional investors and hedge funds own 31.59% of the company's stock.

Insider Transactions at SOPHiA GENETICS

In other news, Chairman Jurgi Camblong sold 8,500 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $7.61, for a total transaction of $64,685.00. Following the completion of the sale, the chairman owned 3,444,322 shares of the company's stock, valued at $26,211,290.42. This trade represents a 0.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $7.60, for a total value of $38,000.00. Following the transaction, the chief technology officer directly owned 182,171 shares in the company, valued at $1,384,499.60. The trade was a 2.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 313,592 shares of company stock valued at $1,927,565. Company insiders own 4.88% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research raised their price target on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. Finally, HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $10.00.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH opened at $8.65 on Wednesday. The firm has a fifty day simple moving average of $6.33 and a 200 day simple moving average of $5.37. SOPHiA GENETICS SA has a 1-year low of $3.10 and a 1-year high of $8.85. The stock has a market capitalization of $725.65 million, a PE ratio of -7.52 and a beta of 0.96. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. On average, research analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

SOPHiA GENETICS Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source